Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay

R. Villa, N. Zaffaroni, F. C. Giuliani, G. Colella, O. Sanfilippo, R. Silvestrini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A short-term antimetabolic assay based on the interference with 3H-thymidine and 3H-uridine incorporation after 3 hours of in vitro treatment and was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-Iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound Doxorubicin (DX) against 44 human colorectal carcinomas. IDX had a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose of IDX required to induce a significant antimetabolic effect obtained by extrapolation from the dose-effect plots for each drug was 1/10 that of DX (2.3 μg/ml vs 23 μg/ml). When the relative activities of the two drugs on the same tumor specimen were determined, there was 71% to 86% overall agreement, depending on the concentration used. Lack of agreement was always attributed to sensitivity to IDX and resistance to the parent compound.

Original languageEnglish
Pages (from-to)105-108
Number of pages4
JournalAnticancer Research
Volume10
Issue number1
Publication statusPublished - 1990

Fingerprint

Rectal Neoplasms
Doxorubicin
Uridine
Anthracyclines
Pharmaceutical Preparations
Thymidine
Colorectal Neoplasms
In Vitro Techniques
esorubicin
Neoplasms

Keywords

  • 4'-Iodo-4'-deoxydoxorubicin
  • antimetabolic assay
  • colorectal cancer
  • doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay. / Villa, R.; Zaffaroni, N.; Giuliani, F. C.; Colella, G.; Sanfilippo, O.; Silvestrini, R.

In: Anticancer Research, Vol. 10, No. 1, 1990, p. 105-108.

Research output: Contribution to journalArticle

Villa, R. ; Zaffaroni, N. ; Giuliani, F. C. ; Colella, G. ; Sanfilippo, O. ; Silvestrini, R. / Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay. In: Anticancer Research. 1990 ; Vol. 10, No. 1. pp. 105-108.
@article{11ce24093a634dbc93bf8c904e38ae31,
title = "Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay",
abstract = "A short-term antimetabolic assay based on the interference with 3H-thymidine and 3H-uridine incorporation after 3 hours of in vitro treatment and was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-Iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound Doxorubicin (DX) against 44 human colorectal carcinomas. IDX had a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose of IDX required to induce a significant antimetabolic effect obtained by extrapolation from the dose-effect plots for each drug was 1/10 that of DX (2.3 μg/ml vs 23 μg/ml). When the relative activities of the two drugs on the same tumor specimen were determined, there was 71{\%} to 86{\%} overall agreement, depending on the concentration used. Lack of agreement was always attributed to sensitivity to IDX and resistance to the parent compound.",
keywords = "4'-Iodo-4'-deoxydoxorubicin, antimetabolic assay, colorectal cancer, doxorubicin",
author = "R. Villa and N. Zaffaroni and Giuliani, {F. C.} and G. Colella and O. Sanfilippo and R. Silvestrini",
year = "1990",
language = "English",
volume = "10",
pages = "105--108",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay

AU - Villa, R.

AU - Zaffaroni, N.

AU - Giuliani, F. C.

AU - Colella, G.

AU - Sanfilippo, O.

AU - Silvestrini, R.

PY - 1990

Y1 - 1990

N2 - A short-term antimetabolic assay based on the interference with 3H-thymidine and 3H-uridine incorporation after 3 hours of in vitro treatment and was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-Iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound Doxorubicin (DX) against 44 human colorectal carcinomas. IDX had a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose of IDX required to induce a significant antimetabolic effect obtained by extrapolation from the dose-effect plots for each drug was 1/10 that of DX (2.3 μg/ml vs 23 μg/ml). When the relative activities of the two drugs on the same tumor specimen were determined, there was 71% to 86% overall agreement, depending on the concentration used. Lack of agreement was always attributed to sensitivity to IDX and resistance to the parent compound.

AB - A short-term antimetabolic assay based on the interference with 3H-thymidine and 3H-uridine incorporation after 3 hours of in vitro treatment and was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-Iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound Doxorubicin (DX) against 44 human colorectal carcinomas. IDX had a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose of IDX required to induce a significant antimetabolic effect obtained by extrapolation from the dose-effect plots for each drug was 1/10 that of DX (2.3 μg/ml vs 23 μg/ml). When the relative activities of the two drugs on the same tumor specimen were determined, there was 71% to 86% overall agreement, depending on the concentration used. Lack of agreement was always attributed to sensitivity to IDX and resistance to the parent compound.

KW - 4'-Iodo-4'-deoxydoxorubicin

KW - antimetabolic assay

KW - colorectal cancer

KW - doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=0025216248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025216248&partnerID=8YFLogxK

M3 - Article

C2 - 2334114

AN - SCOPUS:0025216248

VL - 10

SP - 105

EP - 108

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -